• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Herr Amy E. claimed ownership of 1,860 shares (SEC Form 3)

    2/7/25 4:55:32 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Herr Amy E.

    (Last) (First) (Middle)
    614 MCKINLEY PLACE NE

    (Street)
    MINNEAPOLIS MN 55413

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    BIO-TECHNE Corp [ TECH ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 1,860 I By significant other
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 08/08/2025 Common Stock 3,256 $44.33 I By significant other
    Stock Option (Right to Buy) (1) 08/07/2026 Common Stock 6,636 $47.6 I By significant other
    Stock Option (Right to Buy) (1) 08/05/2027 Common Stock 4,472 $66.97 I By significant other
    Stock Option (Right to Buy) (2) 08/06/2028 Common Stock 2,076 $120.46 I By significant other
    Stock Option (Right to Buy) (3) 08/15/2029 Common Stock 2,104 $94.52 I By significant other
    Stock Option (Right to Buy) (4) 08/15/2030 Common Stock 1,084 $84.61 I By significant other
    Stock Option (Right to Buy) (5) 08/15/2034 Common Stock 1,468 $74.91 I By significant other
    Restricted Stock Units (6) (6) Common Stock 237 (7) I By significant other
    Restricted Stock Units (8) (8) Common Stock 480 (7) I By significant other
    Explanation of Responses:
    1. Fully vested.
    2. 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and 516 shares vest on 8/6/2024.
    3. 528 shares vest on 8/15/2023 and 8/15/2025; 524 shares vest on 8/15/2024 and 8/15/2026.
    4. 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
    5. 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
    6. 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026.
    7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
    8. 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.
    Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney filed herewith. 02/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TECH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    2/8/2024$80.00Sector Outperform
    Scotiabank
    2/2/2024$65.00Buy → Hold
    Stifel
    12/7/2023$80.00Buy
    UBS
    8/28/2023Outperform
    William Blair
    More analyst ratings

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

      MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes

      5/8/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be r

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bio-Techne Corp

      10-Q - BIO-TECHNE Corp (0000842023) (Filer)

      5/8/25 4:30:29 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - BIO-TECHNE Corp (0000842023) (Filer)

      5/7/25 6:30:11 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne Corp filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIO-TECHNE Corp (0000842023) (Filer)

      5/6/25 4:30:10 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      5/5/25 4:18:21 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      4/7/25 4:25:38 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herr Amy E. exercised 1,976 shares at a strike of $44.33 and sold $122,691 worth of shares (1,860 units at $65.96) (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      2/18/25 4:49:57 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bio-Techne Corp

      SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

      11/14/24 1:22:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/13/24 5:00:46 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/9/23 11:12:40 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    See more

    $TECH
    Financials

    Live finance-specific insights

    See more
    • Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

      MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

      2/4/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

      MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

      4/30/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

      MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

      1/5/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be r

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results

      MINNEAPOLIS, April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time:            8:00 a.m. CDT Date:                      May 7, 2025 Dial-in:    1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID:      13753150 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-3

      4/15/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bio-Techne downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Bio-Techne from Overweight to Sector Weight

      4/9/25 8:34:38 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Bio-Techne with a new price target

      Evercore ISI initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $75.00

      3/18/25 7:57:08 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Bio-Techne from Outperform to Neutral and set a new price target of $68.00 from $88.00 previously

      2/19/25 7:06:32 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care